Diagnostic and therapeutic epitope, and transgenic plant
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-049/00
A61K-039/35
A61K-038/08
C07K-014/415
C07K-004/10
출원번호
US-0556208
(2006-11-03)
등록번호
US-8329144
(2012-12-11)
우선권정보
GB-9923306.6 (1999-10-01)
발명자
/ 주소
Anderson, Robert Paul
Hill, Adrian Vivian Sinton
Jewell, Derek Parry
출원인 / 주소
Isis Innovation Limited
대리인 / 주소
Pepper Hamilton LLP
인용정보
피인용 횟수 :
9인용 특허 :
48
초록▼
A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognized by a T cell receptor that recognizes an epitope comprising sequence 62PQPELPY68 (SEQ ID NO:1), and fusion proteins, pharmaceutical compositions, and kits comprising the same, are provided her
A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognized by a T cell receptor that recognizes an epitope comprising sequence 62PQPELPY68 (SEQ ID NO:1), and fusion proteins, pharmaceutical compositions, and kits comprising the same, are provided herewith. Also provided are methods of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising contacting a sample from the individual with a peptide analogue and determining in vitro whether T cells in the sample recognize the peptide analogue.
대표청구항▼
1. A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognised by a T cell receptor or an antibody that recognises an epitope comprising SEQ ID NO:1 or SEQ ID NO:2, wherein the peptide analogue comprises: Pro-Gln-Pro-Xaa-Leu-Pro-Tyr (SEQ ID NO:79), wh
1. A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognised by a T cell receptor or an antibody that recognises an epitope comprising SEQ ID NO:1 or SEQ ID NO:2, wherein the peptide analogue comprises: Pro-Gln-Pro-Xaa-Leu-Pro-Tyr (SEQ ID NO:79), wherein Xaa is Asp; orXaa-Gln-Pro-Glu-Leu-Pro-Tyr (SEQ ID NO:80), wherein Xaa is Val; orPro-Xaa-Pro-Glu-Leu-Pro-Tyr (SEQ ID NO:81), wherein Xaa is Ser, Ile, or Met; orPro-Gln-Pro-Glu-Leu-Pro-Xaa (SEQ ID NO:85), wherein Xaa is Val. 2. A peptide analogue according to claim 1 wherein the peptide analogue comprises Pro-Gln-Pro-Xaa-Leu-Pro-Tyr (SEQ ID NO:79), wherein Xaa is Asp. 3. A peptide analogue according to claim 1 wherein the peptide analogue comprises: Xaa-Gln-Pro-Glu-Leu-Pro-Tyr (SEQ ID NO:80), wherein Xaa is Val. 4. A peptide analogue according to claim 1 wherein the peptide analogue comprises: Pro-Xaa-Pro-Glu-Leu-Pro-Tyr (SEQ ID NO:81), wherein Xaa is Ser, Ile, or Met. 5. A peptide analogue according to claim 1 wherein the peptide analogue comprises: Pro-Gln-Pro-Glu-Leu-Pro-Xaa (SEQ ID NO:85), wherein Xaa is Val. 6. A peptide analogue according to claim 1 which comprises a non-natural amino acid at the N terminus or C terminus. 7. A composition comprising one or more of the peptide analogues according to claim 1. 8. A pharmaceutical composition comprising a peptide analogue according to claim 1 and a pharmaceutically acceptable carrier or diluent. 9. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: a) contacting a sample from the individual with a peptide analogue according to claim 1; andb) determining in vitro whether T cells in the sample recognise the peptide analogue, wherein recognition by the T cells indicates that the individual has or is susceptible to coeliac disease. 10. A method according to claim 9 wherein the sample is a blood sample. 11. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: a) administering a peptide analogue according to claim 1 to the skin of the individual; andb) detecting the presence of inflammation at the site of administration, wherein detection of inflammation indicates that the T cells of the individual recognise the peptide analogue. 12. A method of treating coeliac disease in an individual comprising administering a peptide analogue according to claim 1 to the individual. 13. A kit comprising: a peptide analogue according to claim 1; anda means to detect the recognition of the peptide analogue by the T cell. 14. A fusion protein comprising a peptide analogue according to claim 1 and other gliadin or non-gliadin sequence. 15. A fusion protein according to claim 14 which comprises a non-natural amino acid at the N terminus or C terminus. 16. A composition comprising one or more of the fusion proteins according to claim 14. 17. A pharmaceutical composition comprising a fusion protein according to claim 14 and a pharmaceutically acceptable carrier or diluent. 18. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: a) contacting a sample from the individual with a fusion protein according to claim 14; andb) determining in vitro whether T cells in the sample recognise the fusion protein, wherein recognition by the T cells indicates that the individual has or is susceptible to coeliac disease. 19. A method according to claim 18 wherein the sample is a blood sample. 20. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: a) administering a fusion protein according to claim 14 to the skin of the individual; andb) detecting the presence of inflammation at the site of administration, wherein detection of inflammation indicates that the T cells of the individual recognise the fusion protein. 21. A method of treating coeliac disease in an individual comprising administering a fusion protein according to claim 14 to the individual. 22. A kit comprising: a fusion protein according to claim 14; anda means to detect the recognition of the fusion peptide by the T cell.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (48)
Shewmaker Christine K. (Davis CA) Kridl Jean C. (Davis CA) Hiatt William R. (Davis CA) Knauf Vic (Davis CA), Anti-sense regulation of gene expression in plant cells.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner.
Ryals John A. (Durham NC) Friedrich Leslie B. (Cary NC) Uknes Scott J. (Apex NC) Ward Eric R. (Basel CHX), Chemically inducible promoter of a plant PR-1 gene.
Hauptmann Randal (Woodland CA) Eschenfeldt William H. (St. Charles IL) English Jami (Aurora IL) Brinkhaus Friedhelm L. (Lisle IL), Enhanced carotenoid accumulation in storage organs of genetically engineered plants.
Lundquist Ronald C. (Minnetonka MN) Walters David A. (Bloomington MN), Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis en.
Cramer Carole Lyn (Blacksburg VA) Weissenborn Deborah Louise (Blacksburg VA), HMG2 promoter expression system and post-harvest production of gene products in plants and plant cell cultures.
Nasrallah Mikhail E. ; Nasrallah June B. ; Thorsness Mary K., Isolated DNA elements that direct pistil-specific and anther-specific gene expression and methods of using same.
Heinemann Stephen F. (La Jolla) Boulter James R. (San Diego) Hollmann Michael (Del Mar) Bettler Bernhard (Solana Beach) Jensen Jan E. (San Diego CA), Isolated nucleic acids encoding glutamate receptor protein.
Sanford John C. (Geneva) DeVit Michael J. (Geneva NY) Bruner Ronald F. (Sewell NJ) Johnston Stephen A. (Durham NC), Method and apparatus for introducing biological substances into living cells.
Fuchs Roy L. (St. Charles MO) Kishore Ganesh M. (Chesterfield MO) MacIntosh Susan C. (St. Louis MO), Method for improving the efficacy of insect toxins.
Marcker Kjeld A. (Eg) Jensen Jens S. (Århus), Method for the expression of genes in plants, parts of plants, and plant cell cultures, and DNA fragments, plasmids, and.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Method for transporting substances into living cells and tissues.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Method for transporting substances into living cells and tissues and apparatus therefor.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Method for transporting substances into living cells and tissues and apparatus therefor.
Dobres Michael S. (Philadelphia PA) Mandaci Sevnur (Ardsley PA), Plant promoter useful for directing the expression of foreign proteins to the plant epidermis.
Schilperoort Robbert A. (Leiden NLX) Hoekema Andreas (Leiden NLX), Process for the incorporation of foreign DNA into the genome of dicotyledonous plants.
Matsuyama Akinobu (Niigata JPX) Nikaido Teruyuki (Niigata JPX) Kobayashi Yoshinori (Niigata JPX), Process for the production of optically active 2-hydroxy acid esters using microbes to reduce the 2-oxo precursor.
Adams Thomas R. (North Stonington CT) Chambers Sheryl A. (Groton CT) Daines Richard J. (Ledyard CT) Gordon-Kamm William J. (Stonington CT) Kausch Albert P. (Stonington CT) Lemaux Peggy G. (Mystic CT), Process of producing fertile transgenic zea mays plants and progeny comprising a gene encoding phosphinothrici.
Logemann Jrgen (Erftstadt DEX) Willmitzer Lothar (Berlin DEX) Schell Josef (Kln DEX), Wound-stimulated DNA-sequence from solanum tuberosum and its use.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.